Silence Therapeutics PLC Sponsored ADR (SLN) has been beaten down lately with too much selling pressure. While the stock has ...

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of ...

Shares of Silence Therapeutics PLC Sponsored ADR (SLN) have gained 34.4% over the past four weeks to close the last trading session at $5.78, but there could still be a solid upside left in the stock ...

Silence Therapeutics PLC Sponsored ADR (SLN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend ...

The Government of New Caledonia issued unanimously the export authorisations for Société Le Nickel up to 2 million tons of nickel ore, which brings its annual export authorisation up to 6 million tons ...

Silence Therapeutics (SLN) shares surged as much as 41% to a 52-week high Monday after the clinical-stage biotechnology company reported quarterly results alongside positive Phase 2 data for its ...

Silence Therapeutics PLC Sponsored ADR (SLN) shares soared 5.8% in the last trading session to close at $21.17. The move was backed by solid volume with far more shares changing hands than in a normal ...

Silence Therapeutics PLC ADR Annual stock financials by MarketWatch. View the latest SLN financial statements, income statements and financial ratios.